NYSE$HIMS
Hims & Hers Health Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2022.
Hims & Hers Health, Inc. reported exceptional performance in Q3 2022, with a 95% increase in revenue year-over-year. Net new subscriptions reached an all-time high, and the company raised its full-year 2022 revenue and Adjusted EBITDA guidance. The company expects Adjusted EBITDA profitability beginning in Q4 2022.
- Revenue was $144.8 million, up 95% year-over-year.
- Net new subscriptions reached an all-time high of over 170,000, ending Q3 2022 with 991,000 subscriptions, up 80% year-over-year.
- Gross margin was 79% compared to 74% for the third quarter 2021.
- The company raises full year 2022 revenue guidance to the range of $519 million to $522 million and Adjusted EBITDA guidance to the range of $(20) million to $(18) million
Headline financials
Revenue & EPS history
Hims & Hers · Revenue · Quarterly
$145M
Revenue by segment
Hims & Hers · $145M total across 2 segments · Q3 2022
- Online Revenue$140M+94.1%96.5%
- Wholesale Revenue$5.06M+136.1%3.5%
Forward guidance
For the fourth quarter 2022, the company expects revenue to be in the range of $159 million to $162 million and Adjusted EBITDA to be in the range of $0 million to $2 million. For the full year 2022, the company expects revenue to be in the range of $519 million to $522 million and Adjusted EBITDA to be in the range of $(20) million to $(18) million.
Tailwinds
- Revenue to be in the range of $159 million to $162 million for Q4 2022.
- Adjusted EBITDA to be in the range of $0 million to $2 million for Q4 2022.
- Revenue to be in the range of $519 million to $522 million for the full year 2022.
- Adjusted EBITDA to be in the range of $(20) million to $(18) million for the full year 2022.
- Adjusted EBITDA margin in the range of 0% to 1% for Q4 2022.
Headwinds
- Adjusted EBITDA to be in the range of $(20) million to $(18) million for the full year 2022.
- Adjusted EBITDA margin in the range of (4)% to (3)% for the full year 2022.
- The guidance constitutes forward-looking statements and actual results may differ materially.
- The company has not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss.
- The ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within the company's control, or others that may arise, cannot be predicted with reasonable certainty without unreasonable effort.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+2.5%
Avg return
Earnings day
+3.8%
Avg return
5 days after
+11.7%
Avg return
30 days after
50%
13 / 26 earnings
Positive
+41.1%
Q4 2023
Best reaction
-22.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.0% | -11.4% | -1.8% | |
| Q4 2025 | -2.8% | -6.4% | +34.5% | |
| Q3 2025 | -3.6% | -7.6% | -9.8% | |
| Q1 2025 | +18.5% | +24.1% | +26.0% | |
| Q4 2024 | -22.3% | -12.1% | -37.8% | |
| Q3 2024 | +1.4% | +15.0% | +66.6% | |
| Q2 2024 | -4.0% | -9.2% | -16.9% | |
| Q1 2024 | +9.7% | +9.1% | +93.2% | |
| Q4 2023 | +41.1% | +37.8% | +65.3% | |
| Q3 2023 | +7.6% | +5.1% | +37.3% | |
| Q2 2023 | -8.7% | -11.7% | -15.2% | |
| Q1 2023 | -11.5% | -10.2% | -23.9% | |
| Q4 2022 | +15.4% | +6.0% | +2.7% | |
| Q3 2022 | +30.1% | +37.2% | +64.7% | |
| Q2 2022 | -3.4% | +9.2% | -0.6% | |
| Q1 2022 | -13.0% | -13.5% | +5.3% | |
| Q4 2021 | +8.0% | +20.5% | +19.8% | |
| Q3 2021 | -7.0% | -1.3% | -26.3% | |
| Q2 2021 | +7.0% | -4.7% | +11.1% | |
| Q1 2021 | +13.7% | +44.9% | +33.1% | |
| Q2 2020 | -8.4% | -7.2% | -21.9% | |
| Q4 2020 | -7.5% | -15.4% | -21.3% | |
| Q3 2020 | +0.1% | +0.0% | +17.5% | |
| Q1 2020 | -0.7% | -0.5% | +0.1% | |
| Q4 2019 | +1.4% | +2.1% | +2.2% | |
| Q3 2019 | +0.0% | +0.3% | -0.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro